RecruitingNCT07513948
Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
DarTTP: an Observational, International, Multicentric Study on Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Enrollment
40 participants
Start Date
Oct 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria4
- patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity <10% with anti-ADAMTS13 antibodies detected);
- aged ≥ 18 years;
- male and female patients;
- treated with daratumumab for iTTP.
Exclusion Criteria2
- patients unwilling or unable to provide their informed consent;
- follow-up < 6 months after daratumumab administration.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07513948